Electroacupuncture vs no treatment
Withdrawals due to adverse events · participants with quiescent IBD
1 finding from 1 review
- no estimate extracted1 study · 34 participantsLow
Findings
What do systematic reviews say?
4,918 questions · 5,537 findings · 1,803 reviews
No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Adalimumab vs active comparators
Withdrawals due to adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
5‐ASA vs placebo
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.5 [0.71, 3.19]3 studies · 297 participantsLow
High dose 5‐ASA vs low dose 5‐ASA
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.04 [0.15, 7.24]1 study · 206 participantsLow
5‐ASA vs purine antimetabolites
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.48 [0.28, 0.83]5 studies · 425 participantsLow
5‐ASA vs anti TNF‐ɑ
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.3 [0.01, 6.84]1 study · 34 participantsVery low
Sulphasalazine vs placebo
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.35 [0.01, 8.38]1 study · 66 participantsVery low
5‐ASA vs no treatment
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 5 [0.25, 101.81]1 study · 110 participantsVery low
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 2.21 [1.28, 3.81]4 studies · 425 participantsLow
Azathioprine or 6‐mercaptopurine vs anti TNF‐ɑ
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with anti TNF‐α (low certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 3.97 [0.92, 17.22]3 studies · 139 participantsLow
Azathioprine or 6‐mercaptopurine vs placebo
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.9 [0.63, 1.29]3 studies · 408 participantsModerate
Anti‐TNF discontinuation vs anti‐TNF continuation
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.29 [0.82, 2.03]8 studies · 2095 participantsVery low
Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.24 [0.42, 3.7]2 studies · 317 participantsVery low
Anti‐TNF dose reduction vs anti‐TNF continuation
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.09 [0.65, 1.82]5 studies · 1084 participantsLow
Herbal treatment vs placebo
Adverse events Post‐intervention · adults with neuropathic pain
It is very uncertain whether herbal treatment changes adverse events Post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
- Herbal medicinal products or preparations for neuropathic pain 2019 · Cochrane Headline outcomes onlyRR 1 [0.55, 1.81]2 studies · 128 participantsVery low
Physical activity vs alpha‐blocker
Withdrawals due to adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Physical activity showed no clear difference in withdrawal due to adverse events compared with alpha‐blockers (low certainty).
1 finding from 1 review
- Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction 2019 · Cochrane Headline outcomes onlyRR 0.86 [0.06, 12.89]1 study · 41 participantsLow
Physical activity vs watchful waiting
Withdrawals due to adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
It is very uncertain whether physical activity changes withdrawal due to adverse events compared with watchful waiting (very low certainty).
1 finding from 1 review
- Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction 2019 · Cochrane Headline outcomes onlyRR 1 [0.59, 1.69]1 study · 56 participantsVery low
Physical activity as part of self‐management programme vs watchful waiting
Withdrawals due to adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
1 finding from 1 review
- Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 362 participantsVery low
Physical activity as part of weight reduction programme vs watchful waiting
Withdrawals due to adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction
It is very uncertain whether physical activity as part of weight reduction programme changes withdrawal due to adverse events compared with watchful waiting (very low certainty).
1 finding from 1 review
- Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction 2019 · Cochrane Headline outcomes onlyRR 1.63 [1.03, 2.57]1 study · 130 participantsVery low
Zinc tape vs magnesium sulphate glycerin
Priimary outcome: adverse events · ulceration caused by nerve damage in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found